Quanterix Corporation
Financials
Valuation Metrics
Quanterix Corporation's Market Cap is $145M. At end of 2025 it was $298M. Ranked #3056 of 3,121 in US market (top 98%), #1409 of 1,463 on NASDAQ (top 96%), #194 of 205 in Health Care Equipment & Services (top 95%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $145M | US#3,056/3,121 Sec#194/205 |
| Revenue | $153M | US#2,632/3,121 Sec#174/205 |
| Net Income | $-123M | US—/3,121 Sec—/205 |
| Total Assets | $320M | US#2,904/3,121 Sec#175/205 |
| Net Assets | $237M | US#2,624/3,121 Sec#155/205 |
| Employees | 450 | US#2,312/3,121 Sec#159/205 |
| Value | ||
| P/B | 0.61x | US#119/3,121 Sec#7/205 |
| P/S | 0.94x | US#674/3,121 Sec#47/205 |
| FCF Yield | -51.15% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -51.90% | US#2,691/3,121 Sec#170/205 |
| ROA | -38.52% | US#2,940/3,121 Sec#192/205 |
| Op. Margin | -86.19% | US#2,724/3,121 Sec#192/205 |
| Revenue Growth | 23.41% | US#584/3,121 Sec#37/205 |
| Financial Health | ||
| Debt Ratio | 34.74% | US#395/3,121 Sec#40/205 |
| Total Debt | $33M | US#2,683/3,121 Sec#161/205 |
| FCF | $-74M | US#2,584/3,121 Sec#184/205 |
| Cash | $44M | US#2,629/3,121 Sec#169/205 |
| Current Ratio | 3.40x | US#681/3,121 Sec#68/205 |
| Performance | ||
| 1Y Return | -44.98% | US#2,808/3,121 Sec#183/205 |
| 1M Return | 3.72% | US#127/3,121 Sec#22/205 |
| From 52W High | -64.99% | US#2,962/3,121 Sec#193/205 |
| 1Y MDD | -69.98% | US#2,957/3,121 Sec#186/205 |
| Trading | ||
| Volume | 969,369 shares | US#1,438/3,121 Sec#89/205 |
| Trading Value | $3M | US#2,822/3,121 Sec#178/205 |
| Per Share | ||
| EPS | $-2.61 | US—/3,121 Sec—/205 |
| BPS | $5.04 | US#2,279/3,121 Sec#141/205 |
Company Info
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.